Written question asked by Baroness Ritchie of Downpatrick (Labour) on Tuesday, 1 September 2026, in the House of Lords. It was due for an answer on Tuesday, 15 September 2026. It was answered by Baroness Merron (Labour) on Friday, 18 September 2026 on behalf of the Department of Health and Social Care.
Drugs
- Question
-
To ask His Majesty's Government what assessment they have made of the impact of Principle 4 of NHS England's commercial framework for new medicines upon the availability of commercial flexibilities for multi-indication medicines.
- Answer
-
No formal assessment has been made. The next consultation on NHS England’s Commercial Framework, currently planned for 2026/27, will seek views on commercial options including indication-specific pricing.
Secondary information
- Type
- Written question
- Reference
- HL2934
- Session
- 2026-27
- Grouped for answer
- Yes
- Subjects
- Drugs
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-09-18 15:26:26 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL2934
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL2934
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL2934